HeyJaredNoor Ul Ain Rehman
- Indexed articles, last 90 days
- 214
- Latest publication
- Sep 28, 2026
- Outlet visibility, for yahoo.com
- Top 1K sites
- Earliest in this view
- Jul 5, 2026
Latest articles
Can Rocheâs Latest Obesity Drug Results Help it Challenge Eli Lilly and Novo Nordisk? (opens the original)
Read excerpt
Roche’s push into the obesity market has received another boost after its experimental drug, enicepatide, helped overweight or obese patients with type 2 diabetes improve blood sugar control while losing an average of 15.5% of their body weight in a mid-stage trial. The results add another potentially important asset to Roche’s efforts to challenge obesity-market leaders Eli Lilly and Company (NYSE:LLY) and Novo Nordisk A/S (NYSE:NVO). Competition is also growing beyond the two incumbents, with
Can JPMorganâs $20 Billion QIA Partnership Strengthen its Global Asset Management Business? (opens the original)
Read excerpt
JPMorgan Chase & Co.’s (NYSE:JPM) asset management arm is set to deepen its relationship with one of the world’s largest sovereign wealth funds through a planned $20 billion partnership with the Qatar Investment Authority (QIA). The preliminary agreement spans both public and private markets, and the company stated that JPMorgan Asset Management will manage $15 billion in customized global equity portfolios for QIA, while another $5 billion initiative will see the two firms provide senior financ
Can J&Jâs Latest Trial Win Strengthen its Neuroscience Business? (opens the original)
Read excerpt
Johnson & Johnson’s (NYSE:JNJ) $14.6 billion acquisition of Intra-Cellular Therapies has gained another potential growth avenue after Caplyta met the main goal of a late-stage study in bipolar mania. J&J said Caplyta significantly reduced symptoms of bipolar mania compared with placebo in the Phase 3 trial. Patients began showing improvement as early as three days after starting treatment, with the benefits maintained through the study’s three-week duration. The study also met a key secondary go
Can AbbVieâs Backing Help ADARx Win Over Biotech IPO Investors at a $1.74 Billion Valuation? (opens the original)
Read excerpt
ADARx Pharmaceuticals is testing investor appetite for another biotech listing, targeting a valuation of as much as $1.74 billion in a U.S. IPO that could raise up to $371.9 million. The San Diego-based RNA drug developer plans to offer 21.9 million shares at between $15 and $17 apiece and list on the Nasdaq under the ticker ADRX. The offering comes with backing from AbbVie Inc. (NYSE:ABBV) has agreed to invest up to $100 million through a concurrent private placement, which ADARx said would giv
Can J&Jâs Partnership Drive More Upside for Nanobiotix? (opens the original)
Read excerpt
Guggenheim has assumed coverage of Nanobiotix S.A. (NASDAQ:NBTX) with a Buy rating and a $64 price target on September 15, putting the company’s Johnson & Johnson-partnered JNJ-1900 at the center of its investment thesis. The analyst’s attention is particularly focused on NANORAY-312, the pivotal Phase 3 study evaluating JNJ-1900 in patients with locally advanced head and neck cancer who are ineligible for platinum-based chemotherapy, with final Phase 3 data expected in the first half of 2027. D
Publishing over time
Last 90 days. Choose a month to open its work.
Recurring subjects
Named in the text we hold. One piece can cover several.
Audience
Top 1K sites
For yahoo.com, the outlet · Measured Aug 1, 2026
Website popularity band, not a count of readers or article views.
About this data
Counts cover the work we have indexed. Tone needs enough text and a confident classification. Excerpts and episode notes are not full articles or transcripts.
Identity or attribution wrong? Suggest a correction.